3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Glioblastoma
94
Glioma
32
Brain Neoplasms
29
Melanoma
21
Neoplasms
17
Astrocytoma
17
Sarcoma, Ewing
7
Ovarian Neoplasms
7
Gliosarcoma
7
Carcinoma, Non-Small-Cell Lung
7
Neuroblastoma
6
Neoplasm Metastasis
6
Medulloblastoma
6
Breast Neoplasms
6
Sarcoma
5
Recurrence
5
Diffuse Intrinsic Pontine Glioma
5
Small Cell Lung Carcinoma
4
Rhabdomyosarcoma
4
Oligodendroglioma
4
Spinal Cord Neoplasms
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Central Nervous System Neoplasms
3
Triple Negative Breast Neoplasms
2
Rhabdoid Tumor
2
Neuroendocrine Tumors
2
Lymphoma, Follicular
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Interventions
lutetium Lu 177 dotatate
3
Octreotide
3
pasireotide
2
lanreotide
2
amino-acid, glucose, and electrolyte solution
2
Everolimus
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
famitinib
1
copper dotatate CU-64
1
arginyllysine
1
Temozolomide
1
Sunitinib
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
PM 01183
1
Oxaliplatin
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Irinotecan
1
Folfox protocol
1
Fluorouracil
1
E-7386
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Gastro-enteropancreatic neuroendocrine tumor
×
Temozolomide
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled